Tba 200fr analyzer

Manufactured by Toshiba

Sourced in Japan

The TBA-200FR analyzer is a laboratory instrument designed for the analysis and measurement of various parameters. It provides accurate and reliable data to support scientific research and testing. The core function of the TBA-200FR is to perform analyses and measurements, but the specific details of its intended use are not provided in this unbiased and factual description.

Automatically generated - may contain errors

Lab products found in correlation

Modular p800, by Roche (1 mentions) Cobas e601, by Roche (1 mentions)

Spelling variants of this product

TBA-200FR (28 citations) TBA-200FR chemical analyzer (2 citations) TBA-200FR automated clinical chemistry analyzer (2 citations)

4 protocols using tba 200fr analyzer

Voriconazole Quantification Using ARK Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

The ARK™ Voriconazole Assay (ARK Diagnostics, Inc., Fremont, CA, USA) is based on competition between the drug in the specimen and voriconazole labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for binding to the antibody reagent. Upon binding to the antibody, G6PDH enzyme activity decreases. However, in the presence of the drug from the specimen, enzyme activity increases in a manner that is directly proportional to the drug concentration. Quantitative analysis of voriconazole was performed using the Roche Modular P800 automated clinical chemistry analyzer (Roche Diagnostics, Basel, Switzerland) and the Toshiba TBA-200FR analyzer (Toshiba Medical Systems Corporation, Tochigi, Japan).

Jeon Y., Han M., Han E.Y., Lee K., Song J, & Song S.H. (2017). Performance evaluation of enzyme immunoassay for voriconazole therapeutic drug monitoring with automated clinical chemistry analyzers. Practical Laboratory Medicine, 8, 86-94.

+ Open protocol

+ Expand

Bioimpedance-Based Assessment of PD Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

Inclusion criteria were: age between 20 and 75 years; duration of PD (automated peritoneal dialysis (APD) or continuous ambulatory peritoneal dialysis (CAPD)) >4 weeks; daily urine output >500 ml; and provision of written informed consent.
Exclusion criteria were: contraindication to bioimpedance measurement (amputation, presence of pacemaker, defibrillator, prosthesis, or metal implants); probable discontinuation of PD or receipt of kidney transplant within 1 year; hypoalbuminemia (serum albumin <3.3 g/dl); severe heart failure (New York Heart Association Functional Classification (NYHA FC) III or IV); combined dialysis modality (PD + intermittent hemodialysis (HD)); pregnancy, lactation; enrollment in other clinical trials within 1 month; uncontrolled hypertension (>160/100 mmHg with more than three anti-hypertensive medications); cardiovascular diseases (cerebral infarction, hemorrhagic infarction, acute myocardial infarction, or unstable angina) and acute infection (pneumonia, peritonitis) within 3 months prior to the trial.
Serum and urine creatinine (Cr) will be measured by the isotope dilution mass spectrometry-traceable method using a TBA 200FR Analyzer (Toshiba, Tokyo, Japan). GFR will be calculated as the average Cr and urea clearance, which is measured by urine collection
[8 (link)].

Baek S.H., Oh K.H., Kim S., Kim D.K., Joo K.W., Oh Y.K., Han B.G., Chang J.H., Chung W., Kim Y.S, & Na K.Y. (2014). Control of fluid balance guided by body composition monitoring in patients on peritoneal dialysis (COMPASS): study protocol for a randomized controlled trial. Trials, 15, 432.

+ Open protocol

+ Expand

Comprehensive Metabolic Profiling in Fasting Participants

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fasting blood samples were collected from the antecubital vein for fasting plasma glucose, insulin, glycosylated hemoglobin (HbA1c), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), urea nitrogen, creatinine, and uric acid measurements. The fasting plasma glucose levels were assessed by the hexokinase method using TBA-200FR analyzer (Toshiba Medical Systems, Tokyo, Japan). Insulin concentration was evaluated by a chemiluminescence immunoassay (Cobas e601; Roche, Basel, Switzerland). HbA1c was quantitated by high-performance liquid chromatography (Bio-Rad Laboratories, Inc., Hercules, CA, USA). TG, TC, HDL-C, and LDL-C concentrations were assessed by specific immunoassays (Cobas e601; Roche, Basel, Switzerland). Serum free fatty acids (FFAs) were detected via an enzymatic method (DiaSys Diagnostic Systems GmbH, Holzheim, Germany). Homeostasis model assessment of insulin resistance (HOMA-IR) was derived as follows: [fasting serum insulin (mU/l) × fasting plasma glucose (mmol/l)]/22.5 [15 (link)]. Serum 1.5-anhydroglucitol (1.5-AG) was measured using an enzymatic assay kit (GlycoMark, Japan).

Zhang W., Wang H., Liu F., Ye X., Tang W., Zhang P., Gu T., Zhu D, & Bi Y. (2021). Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Therapy, 13(4), 679-690.

+ Open protocol

+ Expand

Transabdominal Amniocentesis for Intraamniotic Inflammation

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Transabdominal amniocentesis was performed after the collection of cervical secretions. Amniotic fluid was cultured for aerobic and anaerobic bacteria as well as for genital mycoplasmas (Ureaplasma species and Mycoplasma hominis). The remaining fluid was centrifuged and stored at −70 °C until analysis. Amniotic fluid MMP-8 levels, measured by using commercial ELISA kits (Amersham Pharmacia Biotech, Little Chalfont, Bucks, UK), were determined with a sensitivity of 0.3 ng/mL. Inter- and intra-assay coefficients were <10%. Intraamniotic inflammation was identified by an elevated amniotic fluid MMP-8 concentration (> 23 ng/mL), as previously reported [25 (link), 55 (link), 106 (link)–108 (link)].
Maternal blood was collected immediately after amniocentesis and transported to the clinical laboratory of our hospital. Serum CRP concentrations, measured by using latex-enhanced immunoturbidimetry assays (TBA-200FR analyzer, Toshiba Medical Systems, Tokyo, Japan), were determined with a sensitivity of 0.01 mg/dL. An elevated maternal serum CRP was defined as > 0.7 mg/dL, as previously reported [104 (link), 109 (link)]. The results of maternal serum CRP and cervical fFN measurements and amniotic fluid cultures, but not amniotic fluid MMP-8 concentrations, were available to the attending physicians.

Jeon C., Yoon H, & Agarwal K. (1994). The transcription factor TFIIS zinc ribbon dipeptide Asp-Glu is critical for stimulation of elongation and RNA cleavage by RNA polymerase II.. Proceedings of the National Academy of Sciences of the United States of America, 91(19), 9106-9110.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!